To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk
Department of Oncology, Faculty of Medicine and Health, Örebro University Hospital, Örebro, Sweden.
Sweden Regional Cancer Center, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.
Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
Department of Oncology, Södersjukhuset, Stockholm, Sweden; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
Show others and affiliations
2023 (English)In: Breast Cancer Research and Treatment, ISSN 0167-6806, E-ISSN 1573-7217, Vol. 198, no 2, p. 361-368Article in journal (Refereed) Published
Abstract [en]

PURPOSE: The safety of local estrogen therapy in patients on adjuvant endocrine treatment is questioned, but evidence on the issue is scarce. This nested case-control registry-based study aimed to investigate whether estrogen therapy affects breast cancer mortality risk in women on adjuvant endocrine treatment.

METHODS: In a cohort of 15,198 women diagnosed with early hormone receptor (HR)-positive breast cancer and adjuvant endocrine treatment, 1262 women died due to breast cancer and were identified as cases. Each case was matched with 10 controls. Exposure to estrogen therapy with concurrent use of aromatase inhibitors (AIs), tamoxifen, or both sequentially, was compared between cases and controls.

RESULTS: No statistically significant difference in breast cancer mortality risk was seen in patients with exposure to estrogen therapy concurrent to endocrine treatment, neither in short-term or in long-term estrogen therapy use.

CONCLUSIONS: The study strengthens current evidence on local estrogen therapy use in breast cancer survivors, showing no increased risk for breast cancer mortality in patients on adjuvant AIs or tamoxifen.

Place, publisher, year, edition, pages
Springer, 2023. Vol. 198, no 2, p. 361-368
Keywords [en]
Breast cancer, Endocrine therapy, Estrogen therapy, Survivors
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-104140DOI: 10.1007/s10549-023-06871-wISI: 000932729800001PubMedID: 36773184Scopus ID: 2-s2.0-85147831911OAI: oai:DiVA.org:oru-104140DiVA, id: diva2:1736357
Funder
Örebro University
Note

Funding agency:

Bröstcancerförbundet and ALF Funding Region Örebro County

Available from: 2023-02-13 Created: 2023-02-13 Last updated: 2023-05-19Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Sund, MariaValachis, Antonis

Search in DiVA

By author/editor
Sund, MariaValachis, Antonis
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Breast Cancer Research and Treatment
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 42 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf